IGC Pharma, Inc. (NYSEMKT:IGC - Get Free Report) Director James P. Moran acquired 588,235 shares of the firm's stock in a transaction on Wednesday, September 25th. The shares were purchased at an average cost of $0.34 per share, for a total transaction of $199,999.90. Following the completion of the purchase, the director now directly owns 942,402 shares of the company's stock, valued at approximately $320,416.68. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
IGC Pharma Stock Performance
Shares of IGC stock opened at $0.35 on Friday. The company has a market capitalization of $26.34 million, a price-to-earnings ratio of -1.58 and a beta of 1.27. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.16 and a current ratio of 1.77.
Wall Street Analyst Weigh In
Separately, Ascendiant Capital Markets boosted their target price on IGC Pharma from $3.50 to $3.75 and gave the stock a "buy" rating in a report on Tuesday, September 3rd.
Read Our Latest Analysis on IGC
IGC Pharma Company Profile
(
Get Free Report)
IGC Pharma, Inc, a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
